ORUKA THERAPEUTICS, INC. — Income Charts
1 years of history · ending 2024-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Operating Expenses
Income Breakdown
Revenue
—
R&D
$75M
SG&A
—
D&A
$27K
Operating Income
$-88M
EBITDA
$-88M
Interest Expense
$1M
Interest Income
$6M
Other Income/Expense
$4K
Pretax Income
$-84M
Tax Provision
—
Net Income
$-84M
Effective Tax Rate
—
Deferred Tax Assets
—
Deferred Tax Liabilities
—
DTA Valuation Allowance
$21M
Tax Credit Carryforwards
$3M
NOL Carryforwards
$2M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
Operating Lease Cost
$300K
Income YoY Variation
-1107.8%